The sessions will focus on the company's strategic direction, operational transformation, and expansion efforts in Asia, featuring comprehensive insights into specific Asian markets.
Attendees can expect detailed presentations along with opportunities for live interaction during Q&A segments.
In a related announcement, Manulife Asia disclosed a significant uptick in its performance metrics for the fourth quarter (Q4) of 2023 and the year overall. This includes growth in annualised premium equivalent (APE) sales, core earnings, and new business value through contractual service margin (CSM).
For Q4 and the full year, Manulife Asia reported a 14% and 11% increase in core earnings, totalling US$414 million and US$1.5 billion, respectively. This compares favourably to the 2022 figures.
Similarly, APE sales witnessed an 11% rise in Q4 and a 15% increase for the entire year, reaching US$731 million and US$3.3 billion, respectively. These gains primarily stem from robust sales in Hong Kong, Mainland China, and Singapore, despite downturns in Vietnam and Japan. This performance highlights Manulife's strengthening foothold in the Asian market and its substantial role in the company's global operations.
